0. DOCID:30756 SCORE: 0.00380403703723908
DOCNO: 12527493
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
AUTHOR: David Johnson D
AUTHOR: Christopher M Pyke CM
AUTHOR: Deborah L Norris DL
AUTHOR: Graham F Adkins GF
AFFILIATION: Department of Surgery, University of Queensland, Mater Adult Hospital, South Brisbane, Queensland, Australia.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Asian journal of surgery / Asian Surgical Association.
COUNTRY: China
TITLE: Atypical ductal hyperplasia of the breast in young women: two case reports.
PUBDATE: 20030101
Atypical ductal hyperplasia of the breast is a benign proliferative condition that is associated with an increased risk of development of breast cancer in either the ipsilateral or contralateral breast. Following diagnosis at biopsy, respective management options range from observation to chemoprophylaxis to prophylactic surgery. We present two cases in young women, facing prolonged follow-up, one managed with observation only, and the other managed with ipsilateral mastectomy and reconstruction.


1. DOCID:31482 SCORE: 0.00345454243761578
DOCNO: 16286900
OWNER: NLM
STATUS: In-Process
AUTHOR: Joachim Andrassy J
AUTHOR: Christian Graeb C
AUTHOR: Markus Rentsch M
AUTHOR: Karl-Waller Jauch KW
AUTHOR: Markus Guba M
AFFILIATION: Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
PUBTYPE: Journal Article
JOURNALTITLE: Transplantation.
COUNTRY: United States
TITLE: mTOR inhibition and its effect on cancer in transplantation.
PUBDATE: 20050901
A considerable amount of data indicates that transplanted patients are at increased risk for de novo and recurrent cancer. Treatment of this population is difficult. It remains unclear if the immunosuppressive therapy should be continued, tapered or even stopped or if immunosuppressive drugs with antiproliferative properties have beneficial effects in this situation. In various models, mTOR-inhibitors were shown to have immunosuppressive and anti-tumor effects. Here, we have reviewed the current literature trying to clarify if mTOR-inhibition brings advantages for the transplanted patients suffering from tumors.


2. DOCID:31853 SCORE: 0.00315307048161048
DOCNO: 16341982
OWNER: NLM
STATUS: In-Process
AUTHOR: G R Blackledge GR
AFFILIATION: AstraZeneca Pharmaceuticals, Macclesfield, UK. George.Blackledge@astrazeneca.com
PUBTYPE: Journal Article
JOURNALTITLE: Zentralblatt für Gynäkologie.
COUNTRY: Germany
TITLE: Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company.
PUBDATE: 20051201
For a company or institute that wishes to develop new anti-cancer agents, it is necessary to establish a portfolio of agents to reduce the risk of failure. Success rates for developing new agents are low and therefore different biological effect areas should be explored to ensure that at least one agent targeting cancer or a specific histological sub-type of cancer is effectively developed. This paper describes how one pharmaceutical company has developed a range of different agents with the ultimate aim of developing as many of these as is technically feasible into useful new medicines for the treatment of cancer.


3. DOCID:31356 SCORE: 0.00315306167702119
DOCNO: 16296738
OWNER: NLM
STATUS: In-Process
AUTHOR: Rafael Mañon R
AUTHOR: Minesh Mehta M
AFFILIATION: University of Wisconsin, Department of Radiotherapy, K4/B100, 600 Highland Avenue, Madison, WI 53792, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert opinion on drug delivery.
COUNTRY: England
TITLE: Strategies for enhanced radiation delivery in patients with lung cancer.
PUBDATE: 20050101
Since the 1970s primary management for regionally advanced non-small cell lung cancer has shifted from radiotherapy alone to sequential chemoradiation to concurrent chemoradiation. The increase in survival with these approaches has been small; an approximately 3-4 month per decade increase in median survival. Future avenues to improve on these outcomes could involve: i)dose-intense radiotherapy; ii) better target delineation; and iii) combining molecularly targeted agents with optimised radiation therapy. However, to accomplish this, techniques to control tumour motion and decrease toxicity must be developed.


4. DOCID:31741 SCORE: 0.00291956195311317
DOCNO: 16122510
OWNER: NLM
STATUS: In-Process
AUTHOR: Natalie D Shaw ND
AUTHOR: Eddie L Hoover EL
AFFILIATION: Division of Thoracic Surgery, VA Western New York Healthcare System, State University of New York, Buffalo, New York, USA.
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of thoracic surgery.
COUNTRY: Netherlands
TITLE: Postoperative pleural effusion in bronchioloalveolar cancer.
PUBDATE: 20050901
Bronchioloalveolar carcinoma occasionally presents with bronchorrhea and can appear on roentgenogram as cavitary lesions similar to a lung abscess. We present a case of multifocal, cavitary bronchioloalveolar cancer, which was originally treated unsuccessfully as lung abscesses. At surgery, two cavities were identified without evidence of tumor or chronic infection and were left open. The postoperative course was complicated by 5 weeks of massive chest tube drainage, which was finally controlled with radiation and time. This report chronicles our difficulty with diagnosis and management and suggests recommendations for future providers.


5. DOCID:31004 SCORE: 0.00285274381067926
DOCNO: 11897559
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: etiology
QUALIFIER: adverse effects
AUTHOR: Yasuhiro Matsumura Y
AUTHOR: Honnavara N Ananthaswamy HN
AFFILIATION: Department of Immunology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 178, Houston, TX, 77030, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Frontiers in bioscience : a journal and virtual library.
COUNTRY: United States
TITLE: Molecular mechanisms of photocarcinogenesis.
PUBDATE: 20020401
Photocarcinogenesis represents the accumulation of genetic changes as well as immune system modulation, which ultimately lead to the development of skin cancers. The recent advances in molecular and cellular biology have clarified the mechanisms of photocarcinogenesis, including the formation of DNA photoproducts, DNA repair, mutation of proto-oncogenes and tumor suppressor genes, and UV-induced immunosuppression. The understanding and further investigation of photocarcinogenesis is critical to the development of effective prevention and intervention strategies for human skin cancer.


6. DOCID:31111 SCORE: 0.00263300295396197
DOCNO: 12632773
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: secondary
QUALIFIER: pathology
QUALIFIER: secondary
AUTHOR: Amina Mekni A
AUTHOR: Saadia Bouraoui S
AUTHOR: Sami Touati S
AUTHOR: Latifa el Ouertani L
AUTHOR: Ahmed el May A
AFFILIATION: Service d'Immuno-histo-cytologie, Institut Salah Azaïz, Tunis.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: La Tunisie médicale.
COUNTRY: Tunisia
TITLE: [Linguinal metastasis from clear cell carcinoma of the kidney]
PUBDATE: 20020901
Clear cell carcinoma is the most frequent cancer of the kidney (60-80% of cases). This tumour has a great propensity to metastasis. Metastasis lesions appear 15 to 20 years after nephrectomy and differential diagnosis with can be difficult to establish. We report an exceptional case of renal cell carcinoma metastasis to the tongue in a 63-years-old male patient who had a nephrectomy 20 years previously. To our knowledge, this is the second case reported in the literature.


7. DOCID:31140 SCORE: 0.00263300286010669
DOCNO: 12800603
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analogs & derivatives
QUALIFIER: drug therapy
AUTHOR: Toru Sugiyama T
AUTHOR: Michiaki Yakushiji M
AUTHOR: Kazunori Ochiai K
AUTHOR: Kiichiro Noda K
AFFILIATION: Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan. sugiyama@iwate-med.ac.jp
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Oncology (Williston Park, N.Y.)
COUNTRY: United States
TITLE: Japanese ovarian trials: focus on irinotecan.
PUBDATE: 20030501
Irinotecan (CPT-11, Camptosar) has achieved a response rate of 23.6% in recurrent ovarian cancer. Irinotecan/cisplatin combination chemotherapy has shown a response rate of 33% in platinum-resistant ovarian cancer, and 76% when used as the initial regimen for ovarian cancer. Regarding dose-limiting toxicity, although neutropenia and diarrhea were observed, diarrhea was thought to cause no remarkable problems in the combination regimen examined. Based on these results, irinotecan is considered to be a useful drug in chemotherapy for ovarian cancer.


8. DOCID:29826 SCORE: 0.00256247344417317
DOCNO: 12391717
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: therapy
AUTHOR: Jeffrey D White JD
AFFILIATION: Office of Cancer Complementary and Alternative Medicine, Office of the Deputy Director of Extramural Science, National Cancer Institute, National Institutes of Health, Executive Plaza North, Suite 102, Bethesda, MD 20892, USA. jeffreyw@mail.nih.gov
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Primary care.
COUNTRY: United States
TITLE: Cancer: current research in alternative therapies.
PUBDATE: 20020601
Apparent increases in the use of alternative medical interventions by patients with cancer represent a challenge and an opportunity for the conventional medical research establishment and medical practice communities. Conventional cancer researchers are beginning to investigate alternative medical interventions that are used by patients with cancer, and eventually this exploration will generate sufficient data to permit evidence-based recommendations about these modalities.


9. DOCID:30259 SCORE: 0.00254223206457972
DOCNO: 15788989
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: classification
QUALIFIER: diagnosis
AUTHOR: B Vindigni B
AUTHOR: P Galgani P
AFFILIATION: Sezione Anatomia Patologica, AO Senese, Siena.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Minerva gastroenterologica e dietologica.
COUNTRY: Italy
TITLE: [Gastric dysplasia: classification and clinical characteristics]
PUBDATE: 20041201
Gastric dysplasia is considered to be the morphologic expression of the penultimate stage in gastric carcinogenesis. The clinical importance has been underscored until the close association with gastric cancer was established. Nevertheless, similar lesions are considered as high grade dysplasia by Western pathologists and as carcinoma by Japanese pathologists, using the Japanese group classification. Padova classification, Vienna classification and Vienna revisited, try to overcome these differences; because of this disagreement therapeutic guidelines are also controversial and differences in the incidence of early stages of gastric cancer and its outcome were reported.


10. DOCID:29836 SCORE: 0.0025422240991277
DOCNO: 16039252
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pathology
QUALIFIER: pathology
AUTHOR: Mitsuru Yoshino M
AUTHOR: Kenzo Hiroshima K
AUTHOR: Shinichiro Motohashi S
AUTHOR: Kiyoshi Shibuya K
AUTHOR: Akira Iyoda A
AUTHOR: Yasuo Sekine Y
AUTHOR: Takehiko Fujisawa T
AFFILIATION: Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of thoracic surgery.
COUNTRY: Netherlands
TITLE: Papillary carcinoma of the thymus gland.
PUBDATE: 20050801
In 1999, the World Health Organization introduced a new classification of a rare thymic cancer called papillary adenocarcinoma of the thymus gland. In this study we report on a case of papillary thymic carcinoma in a 29-year-old woman. Histologically, the tumor consisted of a papillary component admixed with a solid component, a component that is commonly found in type A thymoma.


11. DOCID:31671 SCORE: 0.00242490291051087
DOCNO: 15050952
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Signal Transduction
DESCRIPTOR: Zebrafish Proteins
QUALIFIER: drug therapy
QUALIFIER: drug therapy
QUALIFIER: drug effects
QUALIFIER: pharmacology
AUTHOR: Richard J Gilbertson RJ
AFFILIATION: Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. Richard.Gilbertson@stjude.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The lancet oncology.
COUNTRY: England
TITLE: Medulloblastoma: signalling a change in treatment.
PUBDATE: 20040401
Medulloblastoma is the most common malignant brain tumour that occurs during childhood. Multimodality treatment regimens have substantially improved survival in this disease; however, the tumour is incurable in about a third of patients with medulloblastoma, and current treatment has a detrimental effect on long-term survivors. Drugs that target cell-signalling pathways provide an alternative to conventional cytotoxic approaches to treatment of cancer. Several pathways have been implicated in medulloblastoma formation, and knowledge of these is now being used to develop new ways of treating children with medulloblastoma.


12. DOCID:28966 SCORE: 0.00232867213149754
DOCNO: 11990856
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Pain
QUALIFIER: physiopathology
QUALIFIER: physiopathology
AUTHOR: Patrick W Mantyh PW
AUTHOR: Denis R Clohisy DR
AUTHOR: Martin Koltzenburg M
AUTHOR: Steve P Hunt SP
AFFILIATION: Department of Preventive Sciences, University of Minnesota, Minneapolis 55455, USA. manty001@tc.umn.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Molecular mechanisms of cancer pain.
PUBDATE: 20020301
Pain is the most disruptive influence on the quality of life of cancer patients. Although significant advances are being made in cancer treatment and diagnosis, the basic neurobiology of cancer pain is poorly understood. New insights into these mechanisms are now arising from animal models, and have the potential to fundamentally change the way that cancer pain is controlled.


13. DOCID:31697 SCORE: 0.00232676078887787
DOCNO: 12435046
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: immunology
QUALIFIER: therapy
AUTHOR: Dmitry I Gabrilovich DI
AFFILIATION: H Lee Moffitt Cancer Center, University of South Florida, Tampa 33612, USA. GabrilDI@moffitt.usf.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Dendritic cell vaccines for cancer treatment.
PUBDATE: 20021001
The success of cancer immunotherapy depends on two major factors: adequate tumor-specific antigens and a vehicle capable of inducing a tumor-specific immune response by effective delivery of these antigens. Dendritic cells (DCs) are the most powerful antigen presenting cells, and because of their unique characteristics, these cells are actively used in cancer immunotherapy. In this review we describe recent data regarding different methods of loading these cells with tumor-associated antigens, including RNA or DNA transfer. We will discuss requirements for DC activation as pre-requisite for the success of cancer immunotherapy.


14. DOCID:29093 SCORE: 0.00231800730110603
DOCNO: 12163853
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: epidemiology
QUALIFIER: physiology
AUTHOR: Christopher J Portier CJ
AFFILIATION: Environmental Toxicology Program, National Institute of Environmental Health Sciences, PO Box 12233, Research Triangle Park, NC 27709, USA. portier@niehs.nih.gov
PUBTYPE: Editorial
JOURNALTITLE: Neuro endocrinology letters.
COUNTRY: Sweden
TITLE: Comments on the International Symposium on Light, Endocrine Systems and Cancer.
PUBDATE: 20020701
A conference was held at the University of Cologne on May 2-3, 2002, to discuss the strength-of-the-evidence supporting a linkage between light, endocrine systems and cancer. This overview of the conference is intended to summarize some of the key elements of the conference and to indicate both conclusions and research gaps identified by this reviewer.